Related Experiment Video
Updated: Jun 21, 2026
09:29
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Interferon-beta(1b) treatment in neuromyelitis optica
Masami Tanaka1, Keiko Tanaka, Mika Komori
1MS Center, Utano National Hospital, Kyoto, Japan. tanaka@unh.hosp.go.jp
European Neurology
|July 11, 2009
Summary
Interferon-beta(1b) effectively reduced relapses in multiple sclerosis (MS) patients but not in neuromyelitis optica (NMO) patients. NMO patients also showed increased disability progression with this treatment.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacology
Background:
- Interferon-beta(1b) (IFN-beta(1b)) is a confirmed treatment for multiple sclerosis (MS).
- Its efficacy in neuromyelitis optica (NMO) patients remains unestablished.
- This study investigates IFN-beta(1b)'s impact on disease activity and disability in MS and NMO.
Purpose of the Study:
- To evaluate the effectiveness of interferon-beta(1b) treatment in reducing disease exacerbation and disability progression.
- To compare the treatment outcomes between patients with relapsing-remitting multiple sclerosis (RRMS) and neuromyelitis optica (NMO).
Main Methods:
- A retrospective review of 104 patients (69 RRMS, 35 NMO) treated with IFN-beta(1b).
- Assessment of relapse numbers and annualized relapse rates before and after treatment.
- Evaluation of changes in Kurtzke's Expanded Disability Status Scale (EDSS) scores one year post-treatment.
Main Results:
- IFN-beta(1b) significantly decreased relapse numbers in RRMS patients (p < 0.00001).
- No significant reduction in relapse numbers was observed in NMO patients (p = 0.5601).
- NMO patients exhibited a greater increase in EDSS scores post-treatment compared to RRMS patients (p = 0.0225).
Conclusions:
- Interferon-beta(1b) treatment is not effective for reducing relapses in NMO patients.
- IFN-beta(1b) treatment did not prevent disability progression in NMO patients and may worsen it.
- The findings suggest distinct therapeutic responses to IFN-beta(1b) between MS and NMO.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...